Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Atara Biotherapeutics Has Slumped in 2019

By George Budwell - Jul 9, 2019 at 8:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Atara's shares have collapsed this year. Here's why.

What happened

Atara Biotherapeutics ( ATRA -5.11% ), a clinical-stage cell therapy company, has lost an eye-popping 42% of its value over the first six months of 2019, according to data from S&P Global Market Intelligence. What's been weighing on the biotech's shares this year?

Atara's shares have slumped in response to the news that its experimental, off-the-shelf cell therapy tab-cel -- indicated for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disease -- is experiencing slower-than-expected enrollment in its late-stage program. Compounding matters, the biotech's founder and first CEO, Isaac Ciechanover, announced his retirement earlier this year, which is a rather unsettling development ahead of a key data readout.

Magnified round cell-like balls.

Image Source: Getty Images.

So what

Atara, though, appears to have landed firmly on its feet with the hire of Novartis executive Dr. Pascal Touchon as its new president, CEO, and member of the board of directors. Touchon is clearly a first-round draft pick, given his leadership role in overseeing the launch of Novartis' adoptive cell therapy Kymriah. In short, this is a stellar addition to Atara's brain trust from an experience standpoint.

Having said that, the biotech also lost its global head of research and development, Dr. Dietmar Berger, at the end of May. That's a lot of managerial turnover for a small-cap biotech barreling toward its first major top-line data release.

Now what

Should investors take advantage of this hefty drop in Atara's share price? While there's a lot to be said about the first company that can successfully bring an off-the-shelf T cell therapy to market, Atara's ongoing management churn and clinical trial enrollment issues are worrisome. These issues may not be linked at the end of the day, but two top executives leaving at this critical juncture is an odd occurrence, to put it mildly. Investors, in kind, might want to stick to the safety of the sidelines while this story plays out.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Atara Biotherapeutics, Inc. Stock Quote
Atara Biotherapeutics, Inc.
$17.09 (-5.11%) $0.92

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/04/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.